ibidi Product News: Long-Term Culture and High-Resolution Microscopy of Spheroids and Suspension Cells in One Dish

/in , , , /by

Munich, Germany – The ibidi µ-Dish 35 mm, high Bioinert provides a completely new solution for all scientists who want to combine long-term culture and high-resolution microscopy of living spheroids or suspension cells in one single dish. The Bioinert surface is a thin polyol hydrogel layer that is covalently bound to the ibidi Polymer Coverslip of the µ-Dish 35 […]

Read more →

ZEISS presents new enhanced software technology

/in , , , , /by

ZEISS ZEN Connect provides information from all dimensions of a sample JENA/Germany ZEISS introduces new software modules with enhanced imaging technology: ZEISS ZEN Connect is especially useful for, but not limited to, structural analysis, examination of cellular processes, localization of cells, and much more. The proven ZEISS ZEN software combines numerous functions for day-to-day work […]

Read more →

Pressure BioSciences, Inc. Announces First Contract Utilizing Recently Acquired High Pressure Technology from BaroFold, Inc.

/in , , , /by

International Biopharma Client to Evaluate PBI’s Patented PreEMT™ Platform to Enhance Manufacturing Process and Improve Quality of Key Protein Therapeutic Drug Candidate                                                    South Easton, MA – Pressure BioSciences, Inc. (OTCQB: […]

Read more →

BioLamina launches a cell therapy grade stem cell culture matrix,Biolaminin 521 CTG, bridging discovery and clinical cell therapy

/in , /by

STOCKHOLM — BioLamina (Stockholm) is currently undergoing an exciting phase entering the growing cell and gene therapy reagents industry. In order to meet the growing demand for documentation and traceability required for the manufacture of cells for therapy, BioLamina has launched a cell therapy grade (CTG) laminin substrate for clinical use, Biolaminin 521 CTG. “This is a […]

Read more →

One revolutionary system offers superior protein yields, consistent results, a streamlined workflow and scales from discovery to production CARLSBAD, Calif., May 2, 2018 /PRNewswire/ — Historically, undefined insect media components such as yeastolate have made it challenging to achieve consistent results and protein yields across multiple experiments. These factors can significantly slow vaccine development at a time when manufacturers are under pressure to develop vaccines faster and more efficiently. Focused on removing barriers to vaccine development and production, Thermo Fisher Scientific announced today its Gibco ExpiSf system, the first-ever chemically defined insect protein expression system. The revolutionary ExpiSf system brings together the company’s Gibco media technology, Lipofectamine transfection technology and molecular biology expertise to deliver three times more protein and consistent results. Unlike other systems, ExpiSf has been optimized for the generation of high-quality baculovirus using a suspension-based transfection protocol that delivers protein in half the time compared to traditional insect platforms. The superior performance enables customers to realize significant time savings without sacrificing quality and reproducibility across experiments. “The new ExpiSf Expression System offers a convenient virus generation and protein expression cell line in only two steps, for both secreted and intracellular proteins,” commented Xuan Droz, Ph.D., project leader, Redbiotec AG. “We predict that using the ExpiSf system will save us about 30 percent in the time taken for protein expression and make cell maintenance simpler.” Available now, ExpiSf has many advantages over alternative insect expression platforms: > 300 percent higher protein yield: In performance tests against five competing insect media, the ExpiSf System demonstrated greater protein expression – delivering 3x more protein. Consistent results: Chemically defined, animal-origin free, yeastolate-free growth medium supports consistent cell growth and protein expression, run after run. One optimized system: Fully-integrated platform removes the need to optimize individual components, saving time and cost. Streamlined workflow: The ExpiSf system simplifies baculovirus production to deliver protein in half the time, 6-10 days, compared to 10-20 days via classical techniques. Scales from discovery to production: The scalability of ExpiSf system accelerates development by delivering equivalent cell growth and protein volumetric yield from small to large scale, making the system well-suited for both discovering new therapies and producing them in large quantities. “The ExpiSf Expression System is the newest member of the Expi family delivering superior protein expression and consistent performance in Sf9 cells,” commented Amy Butler, vice president and general manager, Cell Biology at Thermo Fisher Scientific. “ExpiSf is the first-ever chemically defined insect expression system that enables our customers to streamline vaccine development from the bench to the clinic. The system is also suitable for applications in basic research where protein structure and/or function is being studied, for example, in structural biology.” ExpiSf System Components ExpiSf Expression System Starter Kit – Includes all of the reagents necessary to generate recombinant baculovirus and express proteins with the system. The ExpiSf system, related products and training course are available to order at www.thermofisher.com/expisf ExpiSf CD Medium – A GMP-manufactured, chemically defined, yeastolate-free, animal origin-free (AOF) high-density insect growth medium. ExpiSf9 Cells – ExpiSf9 is a robust cell line derived from Sf9 cells and adapted for high-density suspension culture in ExpiSf CD Medium. ExpiSf Enhancer – A chemically defined protein expression enhancer that is specifically matched to ExpiSf CD Medium to deliver significantly higher protein yields. ExpiFectamine Sf Transfection Reagent – a next-generation cationic lipid-based reagent for efficient transfection of DNA from insect cells using a faster, simpler protocol than alternative options. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

/in , /by

One revolutionary system offers superior protein yields, consistent results, a streamlined workflow and scales from discovery to production  CARLSBAD, Calif. — Historically, undefined insect media components such as yeastolate have made it challenging to achieve consistent results and protein yields across multiple experiments. These factors can significantly slow vaccine development at a time when manufacturers are under […]

Read more →

Bio-Rad Expedites Disease Biomarker Discovery and Drug Development with the Launch of Bio-Plex Pro Human Cytokine Screening Panel

/in , , , /by

The Immunoassay is the Market’s First Validated High-Performance Multiplex Screening Panel The Bio-Plex Pro Human Cytokine Screening Panel is a multiplex assay that can accurately and reproducibly quantify up to 48 analytes involved in complex biological networks in a single assay. HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the Bio-Plex […]

Read more →

BIOSERA and Alliance Global Group sign an exclusive distribution agreement

/in , , , /by

Dubai BIOSERA (France) signed an exclusive distribution agreement with Alliance Global to bring their highest quality serum portfolio to AGBL’s market. “BIOWEST’s diverse serum and cell culture media products will complement the AGBL Cell Biology range of products and support our customers in academia, governmental and industrials markets.” said Fatima Kakal, Product Manager Cell and […]

Read more →

Agilent Announces Real-Time, Live-Cell ATP Rate Assay Kit

/in , , , /by

New Assay Expands Application Range of Agilent Seahorse XF Technology SANTA CLARA, Calif. Agilent Technologies Inc. (NYSE: A) today announced the Agilent Seahorse XF Real-Time ATP Rate Assay Kit, a new product that will enable biologists to enhance their understanding of how live-cells function in real-time. The Seahorse XF Real-Time ATP Rate Assay Kit enables […]

Read more →

Thermo Fisher Scientific Signs New Agreements to Expand Oncomine Dx Target Test

/in , /by

Daiichi Sankyo and Takeda Pharmaceuticals to leverage FDA-approved test for clinical trials and drug development programs CARLSBAD, Calif. — Thermo Fisher Scientific announced today it has signed new agreements with Daiichi Sankyo and Takeda Pharmaceuticals designed to expand the clinical utility of Oncomine Dx Target Test in support of clinical trials and drug development programs at each of the firms. […]

Read more →

LGC acquires BioAutomation Corporation

/in , , , /by

LGC has today announced a further strengthening of its nucleic acid chemistry (NAC) offering with the acquisition of BioAutomation Corporation (BioAutomation), manufacturer of the renowned MerMade oligo synthesis instruments. This investment follows LGC’s acquisitions of Biosearch, Prime Synthesis and LINK Technologies, and will drive further growth in the oligonucleotide reagent and synthesised oligonucleotides markets. Brian Kim, President and Managing […]

Read more →